GWPH News and Press, GW Pharmaceuticals Plc From 11/03/20

GW Pharmaceuticals (GWPH) has initiated U.S. Phase 3 trial for nabiximols in multiple sclerosis ((MS))-associated spasticity. The 446-subject study will evaluate the safety and efficacy of nabiximols for spasm frequency over a 12-week period. The first patient is now screened and in baseline ...

GW Pharmaceuticals plc (Nasdaq: GWPH) stock was rising over 6% in early trading as the company delivered solid third-quarter results.  The company reported total revenue of $137.1 million for the quarter ending September 30, 2020, a big jump over the $91.0 million for the sam...

GW Pharmaceuticals (GWPH): Q3 GAAP EPS of -$0.03 beats by $0.02.Revenue of $137.05M (+50.7% Y/Y) beats by $11.08M.Shares +0.8% PM.Press Release For further details see: GW Pharmaceuticals EPS beats by $0.02, beats on revenue

- Total revenue increased 51 percent to $ 137.1 million – - Epidiolex for seizures associated with TSC launch ed in the U.S. - - Nabiximols Phase 3 program in MS spasticity now recruiting - - Conferen...

CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced...

Next Year Could Be a Huge Deal for Marijuana Stocks As 2021 fast approaches, marijuana stock investors are continuing to wonder what could happen next year. In addition, with election day on the horizon, there could be some big changes for the future of the cannabis industry . G...

GW Pharmaceuticals (NASDAQ:GWPH) is scheduled to announce Q3 earnings results on Tuesday, November 3rd, before market open.The consensus EPS Estimate is -$0.06 (-50.0% Y/Y) and the consensus Revenue Estimate is $125.97M (+38.5% Y/Y).Analyst expects cost of product sales of $11.5M;&#...

[[AGCO]], [[ATH]], [[AVNS]], [[AVNT]], [[BHC]], [[BLD]], [[BMCH]], [[CTLT]], [[EAF]], [[EMR]], [[ETN]], [[ETRN]], [[EXC]], [[EXPD]], [[FI]], [[FOXA]], [[GTES]], [[GWPH]], [[HSC]], [[HUM]], [[IT]], [[JCI]], [[JELD]], [[LGIH]], [[LPX]], [[MCK]], [[NSIT]], [[OPCH]], [[RACE]], [[RCM]], [[RHP]], [...

Will Marijuana ETFs Survive In 2020? One of the most volatile sectors in the stock market today is undoubtedly cannabis . It’s no wonder why many investors that like stable positions tend to stay away from top marijuana stocks . As October began, the market was in an upwa...

Investors should study the various revenue streams for "epidiolex". Level of cash reserves important to judge likelihood of future share dilution. Comments at analyst call on future product developments probably the most important look-out. Earnings may give indication of abil...